Skip to main content
Top
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

RETRACTED ARTICLE: Astrocyte-elevated gene-1 mediates insulin-like growth factor 1-induced the progression of cardiac myxoma

Authors: Changcun Fang, Yuwen Shen, Peng Qi, Zhengqin Liu, Min Zhang, Xinyan Pang

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Recently, astrocyte-elevated gene-1 (AEG-1) and insulin-like growth factor 1 (IGF-1) have been involved in the regulation of multiple signaling pathways in tumorigenesis. To date, the detailed mechanisms underlying IGF-1-AEG-1 pathway-induced proliferation and apoptosis in cardiac myxoma (CM) was not reported. In the present study, we used immnohistochemistry, immunoblotting, and qRT-PCR to detect the expression profile of IGF-1 and AEG-1 in 90 CM tissues, and then cultured CM cells were subjected to si-AEG-1, in vitro, and in vivo assays. Our findings showed that IGF-1 and AEG-1 were obviously upregulated in CM tissues and markedly associated with tumor size. When CM cells were treated with si-AEG-1, si-AEG-1 attenuated IGF-1-induced CM cell growth and enhanced cell apoptosis. Mechanically, we validated the expression of AEG-1, p-Erk1/2, and p-Akt increased in CM cells in response to IGF-1 treatment in a time-dependent manner. However, si-AEG-1 affected the expression of these proteins. Functionally, we found the knockdown of AEG-1-inhibited G1/S transition and tumor formation of CM cells. In conclusion, AEG-1 regulates IGF-1-induced proliferation and apoptosis via Erk1/2 and Akt signaling in CM development, which suggests IGF-1-AEG-1 signaling could be recommended to be a useful target to exert anti-tumor effects on CM.
Literature
1.
go back to reference Lim CH, Tan NC, Chia BL, Tan L. Atrial myxoma. Singap Med J. 1977;18:68–75. Lim CH, Tan NC, Chia BL, Tan L. Atrial myxoma. Singap Med J. 1977;18:68–75.
2.
go back to reference Goswami KC, Shrivastava S, Bahl VK, Saxena A, Manchanda SC, Wasir HS. Cardiac myxomas: clinical and echocardiographic profile. Int J Cardiol. 1998;63:251–9.CrossRefPubMed Goswami KC, Shrivastava S, Bahl VK, Saxena A, Manchanda SC, Wasir HS. Cardiac myxomas: clinical and echocardiographic profile. Int J Cardiol. 1998;63:251–9.CrossRefPubMed
3.
go back to reference Ouattara A, Boccara G, Chiche L, Coriat P. Intraoperative diagnosis of an unsuspected left atrial myxoma by transesophageal echocardiography. Anesth Analg. 2002;94:1458–9.PubMed Ouattara A, Boccara G, Chiche L, Coriat P. Intraoperative diagnosis of an unsuspected left atrial myxoma by transesophageal echocardiography. Anesth Analg. 2002;94:1458–9.PubMed
4.
go back to reference Gonzalez-Juanatey C, Regueiro-Abel M, Lopez-Agreda H, Peña-Martínez F, Gonzalez-Gay MA. Giant left atrial myxoma mimicking severe mitral valve stenosis. Int J Cardiol. 2008;127:e110–2.CrossRefPubMed Gonzalez-Juanatey C, Regueiro-Abel M, Lopez-Agreda H, Peña-Martínez F, Gonzalez-Gay MA. Giant left atrial myxoma mimicking severe mitral valve stenosis. Int J Cardiol. 2008;127:e110–2.CrossRefPubMed
5.
go back to reference Rahmanian PB, Castillo JG, Sanz J, Adams DH, Filsoufi F. Cardiac myxoma: preoperative diagnosis using a multimodal imaging approach and surgical outcome in a large contemporary series. Interact Cardiovasc Thorac Surg. 2007;6:479–83.CrossRefPubMed Rahmanian PB, Castillo JG, Sanz J, Adams DH, Filsoufi F. Cardiac myxoma: preoperative diagnosis using a multimodal imaging approach and surgical outcome in a large contemporary series. Interact Cardiovasc Thorac Surg. 2007;6:479–83.CrossRefPubMed
6.
go back to reference Su ZZ, Kang DC, Chen Y, et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 2002;21:3592–602.CrossRefPubMed Su ZZ, Kang DC, Chen Y, et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 2002;21:3592–602.CrossRefPubMed
7.
go back to reference Yoo BK, Emdad L, Su ZZ, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 2009;119:465–77.CrossRefPubMedPubMedCentral Yoo BK, Emdad L, Su ZZ, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 2009;119:465–77.CrossRefPubMedPubMedCentral
8.
go back to reference Lee SG, Jeon HY, Su ZZ, et al. Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma. Oncogene. 2009;28:2476–84.CrossRefPubMed Lee SG, Jeon HY, Su ZZ, et al. Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma. Oncogene. 2009;28:2476–84.CrossRefPubMed
9.
go back to reference Hu G, Chong RA, Yang Q, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor prognosis breast cancer. Cancer Cell. 2009;15:9–20.CrossRefPubMedPubMedCentral Hu G, Chong RA, Yang Q, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor prognosis breast cancer. Cancer Cell. 2009;15:9–20.CrossRefPubMedPubMedCentral
10.
go back to reference Liu K, Guo L, Miao L, et al. Ursolic acid inhibits epithelial–mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells. Anti-Cancer Drugs. 2013;24:494–503.CrossRefPubMed Liu K, Guo L, Miao L, et al. Ursolic acid inhibits epithelial–mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells. Anti-Cancer Drugs. 2013;24:494–503.CrossRefPubMed
11.
go back to reference Li J, Zhang N, Song LB, et al. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 2008;14:3319–26.CrossRefPubMed Li J, Zhang N, Song LB, et al. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 2008;14:3319–26.CrossRefPubMed
12.
go back to reference Weber CE, Li NY, Wai PY, et al. Epithelial-mesenchymal transition, TGF-β, and osteopontin in wound healing and tissue remodeling after injury. J Burn Care Res. 2012;33:311–8.CrossRefPubMedPubMedCentral Weber CE, Li NY, Wai PY, et al. Epithelial-mesenchymal transition, TGF-β, and osteopontin in wound healing and tissue remodeling after injury. J Burn Care Res. 2012;33:311–8.CrossRefPubMedPubMedCentral
13.
go back to reference Mateus C, Palangié A, Franck N, et al. Heterogeneity of skin manifestations in patients with Carney complex. J Am Acad Dermatol. 2008;59:801–10.CrossRefPubMed Mateus C, Palangié A, Franck N, et al. Heterogeneity of skin manifestations in patients with Carney complex. J Am Acad Dermatol. 2008;59:801–10.CrossRefPubMed
14.
go back to reference Raff SB, Carney JA, Krugman D, et al. Prolactin secretion abnormalities in patients with the ‘syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). J Pediatr Endocrinol Metab. 2000;13:373–9.CrossRefPubMed Raff SB, Carney JA, Krugman D, et al. Prolactin secretion abnormalities in patients with the ‘syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). J Pediatr Endocrinol Metab. 2000;13:373–9.CrossRefPubMed
15.
go back to reference Kurtkaya-Yapicier O, Scheithauer BW, Carney JA, et al. Pituitary adenoma in Carney complex: an immunohistochemical, ultra-structural, and immunoelectron microscopic study. Ultrastruct Pathol. 2002;26:345–53.CrossRefPubMed Kurtkaya-Yapicier O, Scheithauer BW, Carney JA, et al. Pituitary adenoma in Carney complex: an immunohistochemical, ultra-structural, and immunoelectron microscopic study. Ultrastruct Pathol. 2002;26:345–53.CrossRefPubMed
16.
go back to reference Sakamoto H, Sakamaki T, Kanda T, et al. Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells. Circ J. 2004;68:488–93.CrossRefPubMed Sakamoto H, Sakamaki T, Kanda T, et al. Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells. Circ J. 2004;68:488–93.CrossRefPubMed
17.
go back to reference He W, He S, Wang Z, et al. Astrocyte elevated gene-1(AEG-1) induces epithelial-mesenchymal transition in lung cancer through activating Wnt/β-catenin signaling. BMC Cancer. 2015;15:1124. He W, He S, Wang Z, et al. Astrocyte elevated gene-1(AEG-1) induces epithelial-mesenchymal transition in lung cancer through activating Wnt/β-catenin signaling. BMC Cancer. 2015;15:1124.
18.
go back to reference Zheng J, Li C, Wu X, et al. Huaier polysaccharides suppresses hepatocarcinoma MHCC97-H cell metastasis via inactivation of EMT and AEG-1 pathway. Int J Biol Macromol. 2014;64:106–10.CrossRefPubMed Zheng J, Li C, Wu X, et al. Huaier polysaccharides suppresses hepatocarcinoma MHCC97-H cell metastasis via inactivation of EMT and AEG-1 pathway. Int J Biol Macromol. 2014;64:106–10.CrossRefPubMed
19.
go back to reference Shan H, Yan R, Diao J, et al. Involvement of caspases and their upstream regulators in myocardial apoptosis in a rat model of selenium deficiency-induced dilated cardiomyopathy. J Trace Elem Med Biol. 2015;31:85–91.CrossRefPubMed Shan H, Yan R, Diao J, et al. Involvement of caspases and their upstream regulators in myocardial apoptosis in a rat model of selenium deficiency-induced dilated cardiomyopathy. J Trace Elem Med Biol. 2015;31:85–91.CrossRefPubMed
20.
Metadata
Title
RETRACTED ARTICLE: Astrocyte-elevated gene-1 mediates insulin-like growth factor 1-induced the progression of cardiac myxoma
Authors
Changcun Fang
Yuwen Shen
Peng Qi
Zhengqin Liu
Min Zhang
Xinyan Pang
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3739-x

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine